HCPCS J0177: Aflibercept hd Injection, Intravitreal 1 mg
HCPCS Level II code J0177 denotes a 1 mg injection of aflibercept hd, used as an intravitreal anti-VEGF therapy for retinal vascular and edema conditions. Nationally, this code is relevant due to the high prevalence of diabetic retinopathy and other retinal diseases that require repeated intravitreal pharmacologic treatment, making it a frequent component of ophthalmology service lines and outpatient procedural billing.
This publication covers coverage and billing considerations for major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of intravitreal aflibercept, how the code maps to typical ophthalmology service settings, and operational billing touchpoints relevant to outpatient clinics and ambulatory surgical centers.
Key takeaways include benchmarks for claim lines that include intravitreal pharmacologic agents, common site-of-service designations, and alignment with diagnostic indications such as diabetic macular edema and related retinal conditions. The document also outlines associated service relationships, for example the procedural component when an intravitreal injection is billed alongside separate procedure codes. This summary is intended for billing managers, ophthalmology clinic administrators, and policy analysts seeking a national view of J0177 usage and billing context.
Customize your policy alerts
Sign up for hcpcs J0177 policy alerts
Get alerted when payer policies referencing J0177 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J0177 represents an injection of aflibercept hd, 1 mg, a pharmacologic agent administered via intravitreal injection. The service type is an intravitreal pharmacologic injection intended for ocular conditions requiring anti-VEGF therapy. The typical site of service is an ambulatory ophthalmology clinic or outpatient surgical/procedural setting where intravitreal injections are performed under sterile conditions.
National Reimbursement Benchmarks
National commercial rates for J0177 cluster around the BUCA average of $343.10, with most large payers showing medians near $311–$324. Blue Cross Blue Shield and Cigna exhibit relatively tight interquartile spreads: BCBS P75–P25 = $362.30 - $312.00 = $50.30 and Cigna P75–P25 = $318.00 - $311.40 = $6.60, indicating consistent middle-range reimbursement. UnitedHealth Group and Aetna display wider dispersion: UnitedHealth Group P75–P25 = $333.10 - $311.40 = $21.70 and Aetna P75–P25 = $323.00 - $82.90 = $240.10, with Aetna showing the largest spread by far.
Payer-specific maxima and minima also vary: Aetna reaches a high of $3,424.00 and a low of $31.50, while UnitedHealth Group and Cigna have maximums of $650.50 and $415.60 respectively. Blue Cross Blue Shield’s rates are concentrated near its median of $335.60, reinforcing its narrow IQR. Overall, BUCA’s mean sits centrally among payer means, reflecting an average commercial position for this code.